SLGL - ソル・ゲル・テクノロジ―ズ (Sol-Gel Technologies Ltd.) ソル・ゲル・テクノロジ―ズ

 SLGLのチャート


 SLGLの企業情報

symbol SLGL
会社名 Sol-Gel Technologies Ltd (ソル・ゲル・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins sirs-t and vered. The Company is designed its proprietary silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert inorganic silica shell which creates an unnoticeable barrier between the active ingredient and the skin.   ソル・ゲル・テクノロジ―ズはイスラエルの製薬企業。独自のマイクロカプセル化技術プラットフォ―ムに基づき、皮膚用医薬品の開発と製品化を行う。臨床試験第2段階を完了した主力製品候補には、膿ほう性ロザケア(酒さ)の治療薬VEREDや、尋常性挫創の治療薬TWINおよびSIRS-Tがある。同社はまた、その他の皮膚用ジェネリック医薬品の開発も手掛ける。   Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.
本社所在地 Weizmann Science Park 7 Golda Meir Street Ness Ziona 7403650 ISR
代表者氏名 Alon Seri-Levy アロン・セリ・レヴィ
代表者役職名 Chief Executive Officer Co-Founder Director
電話番号 +972 8-931-3433
設立年月日 35704
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.sol-gel.com
nasdaq_url https://www.nasdaq.com/symbol/slgl
adr_tso
EBITDA EBITDA(百万ドル) -32.72400
終値(lastsale) 7.2
時価総額(marketcap) 136439769.6
時価総額 時価総額(百万ドル) 115.21580
売上高 売上高(百万ドル) 0.08100
企業価値(EV) 企業価値(EV)(百万ドル) ー
当期純利益 当期純利益(百万ドル) -32.35600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sol Gel Technologies Ltd revenues decreased from $0K to -$93K. Net loss increased 7% to $12.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research_Development Expense increase of 12% to $10.5M (expense) GENERAL AND ADMINISTRATIVE EXPENSES increase of 8% to $2.7M (expense).

 SLGLのテクニカル分析


 SLGLのニュース

   Insights on the Sol-Gel Products Global Market to 2026 - Featuring 3M, CMR Coatings and Porcelain Industries Among Others - ResearchAndMarkets.com  2021/07/05 09:43:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Sol-Gel Products Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering. The global sol-gel products market is expected to grow at with a CAGR greater than 10% during the forecast period. Companies Mentioned IK4-TEKNIKER CHEMAT TECHNOLOGY INC. 3M SOCOMORE SCHOTT AG PPG Industries, Inc. CMR Coatings GAEMA TECH Co., LTD. Nanovations Pty Ltd. Sol-Gel Technologies Ltd. Porcelain Industries Key M
   Other news to note for June 29, 2021  2021/06/29 19:21:00 BioWorld
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Adamis, Anna, Augmenta Bioworks, Biontech, Catalyst, Dydo, Fujitsu Japan, Galderma, Gyroscope, Huyabio International, Iksuda, Ilias, Inxmed, Legochem, Mercaptor Discoveries, Moderna, Pieris, Poxel, Qu Biologics, Redhill, Scancell, Sol-Gel Technologies, Sorrento, Sumitomo Dainippon, Takara, Tessa, TFF, Tiziana Life Sciences.
   Sol-Gel Technologies, Galderma enter license pact for Epsolay and Twyneo  2021/06/28 09:29:11 Seeking Alpha
   Sol-Gel Announces Pipeline Update and Future Development Plans  2021/06/28 09:10:00 Intrado Digital Media
NESS ZIONA, Israel, June 28, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive pre-clinical data for SGT-510, its investigational topical roflumilast drug candidate and provided a corporate update.
   BUSINESS WIRE: Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States  2021/06/28 09:00:02 Finanztreff
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.- Upfront and approval payments of up to $15 million- Tiered royalties ranging from mid- to high-teen percentage of net sales- Sol-Gel option to regain commercialization rights 5 years following first
   Acne Vulgaris Market - Consumer Outlook 2025 | Quest PharmaTech, Inc., Sol-Gel Technologies Ltd  2021/06/18 07:42:00 OpenPR
Global Acne Vulgaris Market: Snapshot Acne vulgaris-one of the commonest skin disorders-has a multifactorial pathogenesis and is found mainly among adolescents. The pathogenetic mechanism usually consists of four key factors: increased sebum productions, follicular epidermal hyperproliferation, the colonization of bacteria Propionibacterium
   US Rosacea Market Size & Forecasts to 2025: Major Players are Vyne Therapeutics, Galderma, Sol-Gel Technologies, and Abbvie  2021/06/09 14:18:00 Intrado Digital Media
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "The US Rosacea Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition)" report has been added to ResearchAndMarkets.com''s offering. The US Rosacea Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition), provides a detailed analysis of the US rosacea market with market sizing and growth pattern.
   Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference  2021/05/27 00:00:00 BioSpace
Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences
   Acne Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Sol-Gel Technologies, Botanix Pharmaceuticals, Novartis Pharmaceuticals and Others  2021/05/24 17:22:01 AB Newswire
   H.C. Wainwright Reiterates a Buy Rating on Sol-Gel Technologies (SLGL)  2021/05/17 10:44:51 Smarter Analyst
H.C. The post H.C. Wainwright Reiterates a Buy Rating on Sol-Gel Technologies (SLGL) appeared first on Smarter Analyst .
   Acne Vulgaris Market - Consumer Outlook 2025 | Quest PharmaTech, Inc., Sol-Gel Technologies Ltd  2021/06/18 07:42:00 OpenPR
Global Acne Vulgaris Market: Snapshot Acne vulgaris-one of the commonest skin disorders-has a multifactorial pathogenesis and is found mainly among adolescents. The pathogenetic mechanism usually consists of four key factors: increased sebum productions, follicular epidermal hyperproliferation, the colonization of bacteria Propionibacterium
   US Rosacea Market Size & Forecasts to 2025: Major Players are Vyne Therapeutics, Galderma, Sol-Gel Technologies, and Abbvie  2021/06/09 14:18:00 Intrado Digital Media
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "The US Rosacea Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition)" report has been added to ResearchAndMarkets.com''s offering. The US Rosacea Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition), provides a detailed analysis of the US rosacea market with market sizing and growth pattern.
   Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference  2021/05/27 00:00:00 BioSpace
Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences
   Acne Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Sol-Gel Technologies, Botanix Pharmaceuticals, Novartis Pharmaceuticals and Others  2021/05/24 17:22:01 AB Newswire
   H.C. Wainwright Reiterates a Buy Rating on Sol-Gel Technologies (SLGL)  2021/05/17 10:44:51 Smarter Analyst
H.C. The post H.C. Wainwright Reiterates a Buy Rating on Sol-Gel Technologies (SLGL) appeared first on Smarter Analyst .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ソル・ゲル・テクノロジ―ズ SLGL Sol-Gel Technologies Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)